7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid
Modify Date: 2024-01-04 10:46:58
![7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid Structure](https://www.chemsrc.com/caspic/444/951163-60-3.png)
7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid structure
|
Common Name | 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid | ||
|---|---|---|---|---|
| CAS Number | 951163-60-3 | Molecular Weight | 505.51800 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H31N3O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acidNemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and (HY-121544) Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia[1][2]. |
| Name | 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and (HY-121544) Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Nemonoxacin has antibacterial activity against Chlamydia pneumoniae with MIC90s of 0.06 μg/mL[1]. Nemonoxacin has highly active against community-acquired MRSA (CA-MRSA) (MIC90: 0.5 and 0.06 μg/ml), and exerts limited activity against (HY-B0356) Ciprofloxacin-resistant MRSA (MIC90: 1 μg/ml), and (HY-B0671) Vancomycin-intermediate MRSA (MIC90: 2 μg/ml)[2]. |
| References |
| Molecular Formula | C24H31N3O9 |
|---|---|
| Molecular Weight | 505.51800 |
| Exact Mass | 505.20600 |
| PSA | 192.62000 |
| LogP | 1.88860 |
|
~71%
7-[(3S,5S)-3-am... CAS#:951163-60-3 |
| Literature: The Procter and Gamble Company Patent: US2007/232804 A1, 2007 ; Location in patent: Page/Page column 9; 10 ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| NEMONOXACIN MALIC ACID |
| 2-HYDROXY-BUTANEDIOIC ACID COMPD. WITH 7-[(3S,5S)-3-AMINO-5-METHYL-PIPERIDIN-1-YL]-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID |
| 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid malate |